Utilizing Saliva Metabolomics for Diagnosing Gastric Cancer and Exploring the Changes in Saliva Metabolites After Surgery.

IF 2.7 4区 医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY OncoTargets and therapy Pub Date : 2024-11-06 eCollection Date: 2024-01-01 DOI:10.2147/OTT.S482767
Zhenhua Dong, Qirui Chen, Dingliang Zhao, Shaopeng Zhang, Kai Yu, Gaojun Wang, Daguang Wang
{"title":"Utilizing Saliva Metabolomics for Diagnosing Gastric Cancer and Exploring the Changes in Saliva Metabolites After Surgery.","authors":"Zhenhua Dong, Qirui Chen, Dingliang Zhao, Shaopeng Zhang, Kai Yu, Gaojun Wang, Daguang Wang","doi":"10.2147/OTT.S482767","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Gastric cancer (GC) is a disease with high prevalence and mortality, but we lack convenient and accurate methods to screen for this disease. Thus, we aimed to search for some salivary biomarkers and explore changes in metabolites in patients' saliva after radical gastrectomy.</p><p><strong>Patients and methods: </strong>A total of 152 subjects were divided into three groups (healthy group, GC group, and one-week postoperative group). After simple processing, saliva samples were analyzed by liquid chromatography-mass spectrometry. First, we used total ion chromatography and principal component analysis to determine the metabolite profiles. Next, <i>t</i>-test, partial least squares discriminant analysis, support vector machine, and receiver operating characteristics curve analysis were performed to identify biomarkers. Then, Fisher discriminant analysis and hierarchical clustering analysis were performed to determine the discriminating ability of biomarkers. Finally, we established a generalized linear model to predict GC based on biomarkers, and used bootstrapping for internal validation.</p><p><strong>Results: </strong>Between the healthy and GC groups, we identified four biomarkers: lactic acid, kynurenic acid, 3-hydroxystachydrine, and S-(1,2,2-trichlorovinyl)-L-cysteine. We used stepwise regression to select five metabolites and develop a model with areas under the curve equal to 0.973 in the training dataset and 0.924 in the validation dataset. Between the GC and one-week postoperative groups, we found two differential metabolites: 19-hydroxyprostaglandin E<sub>2</sub> and DG (14:0/0:0/18:2n6).</p><p><strong>Conclusion: </strong>Differential metabolites were observed among the three groups. GC could be initially diagnosed on the basis of detection of these biomarkers. Moreover, changes in salivary metabolites in postoperative patients could provide important insights for basic studies.</p>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":"17 ","pages":"933-948"},"PeriodicalIF":2.7000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551007/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"OncoTargets and therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/OTT.S482767","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Gastric cancer (GC) is a disease with high prevalence and mortality, but we lack convenient and accurate methods to screen for this disease. Thus, we aimed to search for some salivary biomarkers and explore changes in metabolites in patients' saliva after radical gastrectomy.

Patients and methods: A total of 152 subjects were divided into three groups (healthy group, GC group, and one-week postoperative group). After simple processing, saliva samples were analyzed by liquid chromatography-mass spectrometry. First, we used total ion chromatography and principal component analysis to determine the metabolite profiles. Next, t-test, partial least squares discriminant analysis, support vector machine, and receiver operating characteristics curve analysis were performed to identify biomarkers. Then, Fisher discriminant analysis and hierarchical clustering analysis were performed to determine the discriminating ability of biomarkers. Finally, we established a generalized linear model to predict GC based on biomarkers, and used bootstrapping for internal validation.

Results: Between the healthy and GC groups, we identified four biomarkers: lactic acid, kynurenic acid, 3-hydroxystachydrine, and S-(1,2,2-trichlorovinyl)-L-cysteine. We used stepwise regression to select five metabolites and develop a model with areas under the curve equal to 0.973 in the training dataset and 0.924 in the validation dataset. Between the GC and one-week postoperative groups, we found two differential metabolites: 19-hydroxyprostaglandin E2 and DG (14:0/0:0/18:2n6).

Conclusion: Differential metabolites were observed among the three groups. GC could be initially diagnosed on the basis of detection of these biomarkers. Moreover, changes in salivary metabolites in postoperative patients could provide important insights for basic studies.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
利用唾液代谢组学诊断胃癌并探索手术后唾液代谢物的变化。
目的:胃癌(GC)是一种发病率和死亡率都很高的疾病,但我们缺乏方便准确的方法来筛查这种疾病。因此,我们旨在寻找一些唾液生物标志物,并探讨根治性胃切除术后患者唾液中代谢物的变化:共将 152 名受试者分为三组(健康组、胃癌组和术后一周组)。唾液样本经简单处理后,采用液相色谱-质谱法进行分析。首先,我们使用总离子色谱法和主成分分析法确定代谢物谱。接着,我们进行了 t 检验、偏最小二乘法判别分析、支持向量机和接收者操作特征曲线分析,以确定生物标记物。然后,进行费舍尔判别分析和层次聚类分析,以确定生物标志物的判别能力。最后,我们建立了一个基于生物标志物预测 GC 的广义线性模型,并使用引导法进行内部验证:结果:在健康组和 GC 组之间,我们发现了四种生物标志物:乳酸、犬尿酸、3-羟基水苏碱和 S-(1,2,2-三氯乙烯基)-L-半胱氨酸。我们使用逐步回归法选择了五种代谢物,并建立了一个模型,其训练数据集的曲线下面积等于 0.973,验证数据集的曲线下面积等于 0.924。在 GC 组和术后一周组之间,我们发现了两种不同的代谢物:19-羟基前列腺素 E2 和 DG(14:0/0:0/18:2n6):结论:三组患者的代谢物存在差异。结论:三组患者的代谢物存在差异,可根据这些生物标志物的检测结果初步诊断出 GC。此外,术后患者唾液代谢物的变化可为基础研究提供重要启示。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
OncoTargets and therapy
OncoTargets and therapy BIOTECHNOLOGY & APPLIED MICROBIOLOGY-ONCOLOGY
CiteScore
9.70
自引率
0.00%
发文量
221
审稿时长
1 months
期刊介绍: OncoTargets and Therapy is an international, peer-reviewed journal focusing on molecular aspects of cancer research, that is, the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer. The journal is characterized by the rapid reporting of high-quality original research, basic science, reviews and evaluations, expert opinion and commentary that shed novel insight on a cancer or cancer subtype. Specific topics covered by the journal include: -Novel therapeutic targets and innovative agents -Novel therapeutic regimens for improved benefit and/or decreased side effects -Early stage clinical trials Further considerations when submitting to OncoTargets and Therapy: -Studies containing in vivo animal model data will be considered favorably. -Tissue microarray analyses will not be considered except in cases where they are supported by comprehensive biological studies involving multiple cell lines. -Biomarker association studies will be considered only when validated by comprehensive in vitro data and analysis of human tissue samples. -Studies utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.) should add to the body of knowledge about a specific disease or relevant phenotype and must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. -Bioinformatics studies must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. -Single nucleotide polymorphism (SNP) studies will not be considered.
期刊最新文献
Advances in the Treatment of Rare Mutations in Non-Small Cell Lung Cancer. Analysis of Lymphovascular Infiltration and Tumor-Associated Macrophages in Cervical Cancer Immunoescape. Concentrations of Irinotecan and SN-38 in the Ascites and the Fluid Product of Cell-Free and Concentrated Ascites Reinfusion Therapy 9 Days After Administration of Irinotecan in a Patient with Gastric Cancer: A Case Report. Identification of Cuproptosis-Related Genes for Molecular Subtyping: Predicting Prognostic and Therapeutic Response in Glioma. Four Cases with FUS/CHOP Fusion Gene Products Positive Myxoid Liposarcoma Responding Effectively to Trabectedin Monotherapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1